retatrutide.md Blog
Evidence-based articles about retatrutide, reviewed by our editorial team.
Retatrutide vs Tirzepatide: How Triple Agonists Compare to Dual Agonists
Retatrutide targets three hormone receptors instead of two, producing the largest weight loss seen in clinical trials. Here's how it compares to tirzepatide and what's ahead.
Retatrutide Clinical Trials in 2026: What We Know About the Triple Agonist
retatrutide.md provides a 2026 update on retatrutide clinical trials — phase 3 progress, expected approval timeline, and how results compare to tirzepatide.
Retatrutide Side Effects: What Phase 2 Data Tells Us About Safety
retatrutide.md reviews the known side effects from phase 2 trials and what patients should watch for as phase 3 data emerges.
Triple Agonist Explained: How GLP-1/GIP/Glucagon Medications Work
retatrutide.md explains the science behind triple agonist medications — what each receptor does and why targeting three pathways produces unprecedented weight loss.
Retatrutide and Fatty Liver Disease: Why the Triple Agonist May Transform MASH Treatment
retatrutide.md explores how retatrutide's unprecedented liver fat reduction could change treatment for the 100+ million Americans with fatty liver disease.
The Obesity Medication Pipeline: What's Coming After Ozempic and Mounjaro
retatrutide.md previews every major obesity medication in development — from triple agonists to oral GLP-1s to amylin combinations.